$1.07
+0.07(7.00%)
Mkt Cap $63M
$0.94
$1.87
52-Week Range
At a Glance
AI-generatedVivani Medical, Inc.
8-K
Vivani Medical, Inc. reported fourth quarter and full year 2025 financial results, including a Q4 net loss of $6.6 million and full year net loss of $26.6 million, with cash and equivalents of $16.2 million as of December 31, 2025, supporting operations into mid-2027. The company highlighted successful completion of the LIBERATE-1 first-in-human study and preclinical data for NPM-139 semaglutide implant showing >20% sham-adjusted weight loss for a full year, with Phase 1 study initiation planned for mid-2026.$63M
Market Cap
—
Revenue
-$26M
Net Income
Employees37
Fundamentals
How The Business Makes Money
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
Industry Medical - Devices
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001266806
ISINUS92854B1098
CUSIP92854B109
Phone818 833 5000
Address5858 Horton Street, Alameda, CA, 94608, US
SEC EDGAR